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The abnormal type of cq-antitrypsin, PI (protease inhibitor) type Z, is associated with inclusion bodies in 
the liver, which contain non-secreted ai-antitrypsin. Our studies show that Z protein has an inherent tenden- 
cy to aggregate, even in plasma. Depending upon conditions, from 15 to 70% of the Z protein in plasma 
was in a high-Mr form, compared with 1.5% of M type ai-antitrypsin. The high-M, complex in plasma can- 
not be disaggregated using Triton X detergent or reducing conditions. This increased tendency to aggregate 
can be explained by the mutation affecting, tertiary structure and salt bridge formation in Z protein. We 
have observed this same tendency to aggregate for Mmalton al-antitrypsin, a rarer variant also associated 
with a plasma deficiency. 
al-Antitrypsin dejciency a,-Antitrypsin aggregation Secretion defect 
1. INTRODUCTION 
cYt-Antitrypsin (alAT), or cu-protease inhibitor, 
is a major plasma inhibitor of leukocyte and 
bacterial proteases, particularly elastase. A defi- 
ciency (usually PI type ZZ) occurring in about one 
in 2000-7700 Caucasians leads to an increased risk 
for chronic obstructive pulmonary disease in early 
adult life [ 1] or liver disease in early infancy [2]. A 
characteristic feature of the alAT produced by the 
Z allele is lack of secretion from the liver, resulting 
in the formation of characteristic PAS-positive in- 
clusion bodies [3] which do not readily dissociate 
[4,5]. The reason for this lack of secretion has not 
previously been explained. Two other types of 
crlAT deficiency alleles, PI Mmalton and PI 
Mduarte, occur at about l/ 100 of the frequency of 
the PI Z allele [a], and similarly result in lack of 
secretion of alAT from the liver [7,8]. We report 
here our studies which demonstrate that the 
plasma form of both the Z and Mmalton types of 
alAT shows an unusual tendency to form high-M, 
aggregates. This phenomenon can explain the liver 
retention of alAT and the resulting plasma defi- 
ciency. 
2. MATERIALS AND METHODS 
PI (protease inhibitor) types in plasma or sera 
were identified by isoelectric focusing in 
polyacrylamide gels followed by immunofixation 
[9]. Samples from 5 PI type Z and 4 PI type M in- 
dividuals were used. cvlAT was partially purified 
from delipidated plasma or serum by binding to a 
thiol-Sepharose 4B column activated by 
5 ’ ,5 ‘dithiobis(Znitrobenzoic acid) (DTNB) [lo]. 
A single-step artial purification was used to main- 
tain the cvlAT in as natural a state as possible; 
some purification procedures could remove certain 
forms of alAT. (UIAT was selectively eluted as 
DTNB 1 AT disulphide [lo], from which DTNB 
was removed with 30 mM cysteine-HCl [ 111. 
Monitoring of fractions was carried out by agarose 
electrophoresis [12]. Quantification of alAT and 
other protein markers was carried out by elec- 
troimmuno assay [ 131. Recovery after the thiol col- 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/86/$3.50 0 1986 Federation of European Biochemical Societies 255 
Volume 205, number 2 FEBSLETTERS September 1986 
umn was 8090%. 
The M, distribution of the thiol-purified crlAT, 
was assessed by Ultragel AcA 44 column 
chromatography (LKB, Broma) using one of 
several buffers (table 1). The effect of protein 
(albumin) on the elution pattern was assessed by 
removal of albumin from serum using a Blue 
Sepharose CL6B column [14] prior to thiol 
chromatography. 
The moiecular size of the high-M, complex was 
determined on a Sephacryl S-300 column. At- 
tempts were made to interconvert high- and low-M, 
peaks, by changes in buffer ionic strengths, 
detergents and reduction, as outlined in section 3. 
Tests for the presence of IgA and other proteins in 
the high& complex were carried out using cross- 
immunoelectrophoresis n agarose [15], and SDS- 
acrylamide gel electrophoresis [161. 
Table 1 
Percent of total alAT in each peak collected from 
Ultragel column 
Buffer” Percent of total olAT 
type Peak 1 Peak 2 
M A 2.5 97.5 
C 3.0b 97.0b 
D 1.5, 2.1C 98.5, 97.gc 
E 2.0 98.0 
z A 32.6, 36.4 67.4, 63.6 
B 56.4 43.6 
C 18.7b, 14.gb 81.3b, 8S.lb 
D 69.1, 23.1’ 30.9, 76.9’ 
E 64.2 35.8 
Mmalton D 55.9 44.1 
a A: 0.1 M ‘Iris-HCl, 1 M NaCl (pH 7.4); B: 0.1 M Tris- 
HCI, 0.3 M NaCl (pH 8.1); C: 0.05 M Tris-HCl, 0.05 
M NaCl (pH 8.1); D: 0.05 M Tris-HCl, 0.05 M NaCl 
(pH 7.4); E: 0.05 M KzHP04,0.05 M KHzPOd, 0.008 
M NaOH (pH 6.9) 
b Albumin removed 
’ No thiol column 
Replicate results are for samples from different in- 
dividuals, except for Z buffer C. For Z: C, D (thiol) and 
E are from one individual 
3. RESULTS 
Marked differences in molecular size distribu- 
tion by Uitragel chromatography were noted be- 
tween PI types. PI 2 and PI Mmalton eluted in two 
major peaks, shown as peaks I and II in fig. 1. 
alAT was quantified in each pooled peak. The 
(rlAT in peak I, for PI Z and Mmalton alAT, 
ranged from 15 to 70% of the total culAT 
recovered (table 1). In marked contrast, only 
1.5-3070 of normal PI M crlAT eluted in peak I 
under identical conditions. With buffer A and 1 M 
NaCl, a mean of 34% of PI Z alAT appeared in 
peak I, whereas with buffers B and D (with lower 
salt concentrations) 56 and 69%, respectively, of 
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Fig.1. Gel filtration of thiol-purified (Y~AT PI type 
Mmalton (A), Z (B) and M (C) using 140 ml Ultragel 
AcA 44 column (90x 1.75 cm), buffer D (table 1). Ap- 
prox. 1.3 ml of sample was applied at a flow rate of 0.6 
ml/min. 1.5 ml fractions were collected and quantitated 
for IgA (A), ~2-macroglobulin (A), albumin ( q ), 
prealbumin (m) and alAT (0). These plasma proteins 
were used as molecular mass markers: 160,725,66.3,55 
and 54 kDa, respectively. Fractions of cvlAT eluted in 
two peaks, each of which were pooled (peaks I and II) 
and concentrated. Arrows indicate peaks and dashed 
line in C ofAT of <3 &g/ml. 
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PI Z cwlAT was in peak I. Particularly noteworthy 
is the 64% of &lAT eluted in peak I with buffer E, 
chosen to represent as closely as possible the in- 
tracellular liver ion concentrations and pH. 
Total protein (specifically albumin) appeared to 
influence the elution pattern of alAT. When 
albumin was removed from one PI M and one PI 
Z serum (Blue Sepharose CL6B column), about 
17% of total PI 2 eluted into peak I, compared 
with 69(‘10 when albumin was not removed. 
Preferential removal of peak I on the Blue 
Sepharose column could not alone account for this 
difference: recoveries were 91 and 80%) respective- 
ly, for M and Z culAT. The thiol purification of 
the plasma alone could not be responsible for the 
increased proportion of PI Z cvlAT found in peak 
I. When defibrinated plasma was applied to the 
Ultragel column directly, we observed 23% of total 
Z type alAT in peak I. The high-M, component is 
apparently present even in circulating plasma, The 
thiol column may enhance the tendency to ag- 
gregate, or preferentially remove nonaggregated 
culAT. 
The aggregated Z alAT in peak I showed a 
broad range of apparent i& from greater than 
that of az-macroglobulin (&& 750000) to less than 
that of albumin (A& 66000) (Sepha~ryl S300 
column). 
We were unable to demonstrate conversion of 
peak II (low-M,) from types Z and Mmalton (~1 AT 
to peak I under several conditions. Peak II of M 
and Z =lAT was r~hromatographed using buffer 
E and a higher ionic strength buffer (0.6 M 
&HPO4,0.6 M KHzP04, pH 6.75). An increase in 
the amount of total protein load was also unsuc- 
cessful for converting Z cvlAT peak II: when 
bovine serum albumin was added to peak II (in 
each of buffers C and E) to restore the protein con- 
centration of the original plasma, no conversion to 
peak I was observed. 
The high-it4r peak I of Z and Mmalton alAT, 
once formed, was resistant to conversion into the 
lower&& component under a number of condi- 
tions. Peak I from PI Z plasma (in buffer B) was 
dialyzed and reapplied to the Ultragel column in a 
buffer of lower ionic strength (buffer C), with no 
resulting conversion of peak I to peak II. Peak I of 
each of Z and Mmalton (UIAT was applied to the 
Ultragel column (in buffer D) folIowing reduction 
with 5 mM dithiothreitol (DTT) and 10 mM 
iodoacetate with no effect on the fractionation pat- 
tern. Finally, an attempt was made to dissociate 
the aggregates by treatment with detergent (1% 
Triton X-100 overnight at 4’C) followed by 
Ultragel chromatography in buffer D with 1% 
Triton X-100, with no conversion of peak I to the 
lower-M, form. 
cvl AT has previously been shown to bind to IgA 
[17], IgA was not involved in the formation of the 
highG%& component. There was no consistent rela- 
tion between the IgA and cvlAT concentrations in 
samples applied to and eluted from the Ultragel 
column and the resulting amount of complex 
found in peak I, suggesting that only a small frac- 
tion of IgA can bind crlAT, no matter how much 
cvl AT is present. This was verified by elec- 
trophoresis of peak I of each of M and Z cvlAT in 
agarose followed by crossed electrophoresis into 
anti-IgA or anti-1AT antibody (fig.2). A cathodal 
shoulder, seen with alAT and migrating in the 
same position as IgA, was lost after reduction by 
DTT (fig.3) but this complex accounted for only a 
portion of peak I. A mixing experiment using peak 
I (M alAT) and peak II (Z alAT) was undertaken 
to determine whether IgA or other high-&& pro- 
teins in peak I would bind to cvlAT in peak II. 
There was no cathodal shoulder with crossed elec- 
trophoresis suggestive of binding to IgA, in- 
dicating that IgA present in peak I (M alAT) was 
unable to bind further alAT. The presence of 
other high-M, proteins that bind to or cause ag- 
gregation of culAT is unlikely: the major portion 
of atlAT in peak I migrated in the same position as 
nonaggregated (ulAT (fig.3). Furthermore, SDS- 
acrylamide gel electrophoresis, which solubilizes 
aggregated alAT from liver [5], converted the 
complexed alAT to a component of Mr-55000, 
with a small component of M;> 100000 (as ex- 
pected for &A). There was no evidence of another 
major component in the complex. The aggregated 
form was not due to complexing of (rlAT with the 
leukocyte protein elastase, as tested by Ouchter- 
lony immunodiffusion using antileukocyte elastase 
antibody (kindly provided by Dr James Travis). 
4. DISCUSSION 
Our results have shown that Z cvlAT in plasma, 
like that in liver, shows a pronounced tendency to 
aggregate into a high-&& form, while PI M protein 
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Fig.2. Crossed immunoelectrophoretic analysis of peak I, PI 2 {b,d) and Pi M (a,~) with anti-IgA (a,b) and anti+lAT 
(c,d). Anode to the left in first dimension and to the top in the second dimension. Symbols indicate the mobility of 
plasma proteins: ~bumin (A), cvlAT (AT), transferrin (T) and application (0). 
does not, The amount of complex formed by 2 
(rlAT appears to be inffuenc~ by phosphate ion, 
pH, salt concentration and total protein concentra- 
tion. Aggregation occurs particularly, to a max- 
imum of about 64%) in the presence of pH and salt 
concentrations typical of the hepatic intracellular 
fluid. This same tendency to aggregate is also 
observed for PI Mmalton. The high& compIex 
consists of a large range of Mr values, suggesting 
aggregates of from two to many irlAT molecules, 
which cannot be disrupted by a reducing agent or 
by treatment with Triton X-100 detergent, but can 
be dissociated by boiling in SDS. Apparently 
disulphide bonds are not involved in the complex 
formation and the bonds must be extremely 
strong. 
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The PI 2 deficiency variant results in a plasma 
concentration of about 10-13’0 of that found for 
the normal PI M. According to the studies of the 
half-life of M and Z rrlAT, the decrease is not due 
to increased removal from the plasma 1181 and 
could therefore be due to decreased synthesis or 
decreased secretion. Synthesis of M and Z al AT, 
in an in vitro system, is identical [19], pointing to 
a defect in secretion. The Z &lAT accumulating in 
the hepatocyte, in both rough and smooth en- 
doplasmic reticulum [20] has a carbohydrate com- 
position indicating lack of removal of the 
high-mannose core and lack of addition of the 
final oligosaccharide side chains [Zl]. However, in- 
complete: processing appears to be secondary to the 
basic defect. Studies of m~~roinjection f PI M and 
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Fig.3. Crossed immunoelectrophoresis of peak I, PI M 
with anti_crlAT. Peak I (b) was treated with 5 mM DTT 
and 10 mM iodoacetate (a) for 30 min at room 
temperature. 
Z mRNA into Xenopus oocytes demonstrated lack 
of secretion of the abnormal Z protein with ac- 
cumulation of an intracellular form [22]. Studies 
reported here indicate that this lack of secretion is 
due to formation of very high-M, aggregates. 
Glutamic acid residue 342 in the normal protein 
has been replaced by a lysine in the Z protein [23]. 
The three-dimensional structure of alAT obtained 
from crystal analysis indicates that this substitu- 
tion disrupts a salt bridge important for stabiliza- 
tion of the molecule and decreases the rate of 
folding. Our data suggest hat the cvlAT produced 
immediately begins to form aggregates of increas- 
ing size in the liver, because of the lack of the 
stabilization of the molecule by the salt bridge. 
We have used the fully glycosylated plasma form 
of alAT, rather than the incompletely processed 
form which would be present in the rough en- 
doplasmic reticulum in the liver. However, in the 
studies of production of crlAT in oocytes [24], in 
the presence of tunicamycin, the nonglycosylated 
form of M cvlAT was secreted normally into the 
medium, but the nonglycosylated 2 protein was 
not. The tendency of alAT to aggregate therefore 
is demonstrated with or without the presence of 
oligosaccharide chains on the molecule. The in- 
herent tendency to marked aggregation of cvlAT 
is, we propose, sufficient to produce the typical 
liver inclusions and subsequent plasma deficiency 
of PI Z or PI Mmalton alAT. 
Dr J.-O. Jeppsson, Malmo, Sweden, was helpful 
in advising on protein purification. Study was sup- 
ported by a grant from the Medical Council of 
Canada to D. W .C. Results were reported in part at 
‘~pha-antitrypsin: MoIecules and Medicine’, 
Cambridge, September, 1985. 
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